Open AccessSchiff base Cu(II) complexes as inhibitors of proteasome in human cancer cells
Author(s) -
Katarína Koňáriková,
J Frivaldska,
Helena Gbelcová,
Martin Švéda,
Tomáš Ruml,
Maria Janubova,
Ingrid Žitňanová
Publication year - 2019
Publication title -
bratislavské lekárske listy/bratislava medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.387
H-Index - 32
eISSN - 1336-0345
pISSN - 0006-9248
DOI - 10.4149/bll_2019_107
Subject(s) - cytotoxic t cell , hela , proteasome , chemistry , cancer cell , mtt assay , a549 cell , microbiology and biotechnology , apoptosis , in vitro , biochemistry , cancer research , cancer , biology , genetics
It has been demonstrated that proteasome inhibitors might be potential anticancer drugs. The copper complexes can be used as specific proteasome inhibitors in tumor cells able to induce apoptosis by the ubiquitin-proteasome pathway. The goal of our study was to test the cytotoxic and proteasome inhibitory effects of five Schiff base Cu(II) complexes - [Cu2(sal-D,L-glu)2(isoquinoline)2] . 2C2H5OH (1), [Cu(sal-5-met-L-glu)(H2O)].H2O (2), [Cu(ethanol)2(imidazole)4][Cu2(sal-D,L-glu)2(imidazole)2] (3), [Cu(sal-D,L-glu)(2-methylimidazole)] (4) on human lung carcinoma cells A549, cervix carcinoma cells HeLa and glioblastoma cells U-118MG.